KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $12.7 million.

  • Adaptive Biotechnologies' Accumulated Expenses rose 278.84% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 278.84%. This contributed to the annual value of $15.8 million for FY2024, which is 1573.26% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its Accumulated Expenses stood at $12.7 million for Q3 2025, which was up 278.84% from $9.7 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Accumulated Expenses registered a high of $17.0 million during Q3 2021, and its lowest value of $7.8 million during Q1 2025.
  • Its 5-year average for Accumulated Expenses is $12.0 million, with a median of $12.3 million in 2024.
  • Per our database at Business Quant, Adaptive Biotechnologies' Accumulated Expenses surged by 22281.54% in 2021 and then tumbled by 2782.33% in 2022.
  • Over the past 5 years, Adaptive Biotechnologies' Accumulated Expenses (Quarter) stood at $15.6 million in 2021, then rose by 1.87% to $15.9 million in 2022, then decreased by 14.12% to $13.7 million in 2023, then grew by 15.73% to $15.8 million in 2024, then fell by 19.93% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $9.7 million for Q2 2025, and $7.8 million during Q1 2025.